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INTRODUCTION
Rapidly progressive glomerulonephritis (RPGN) his-
tologically shows extensive crescent formation and is
a clinical situation in which glomerular injury is so
acute and severe that renal function deteriorates over
days or weeks. RPGN is mostly treated with immuno-
suppressive agents, such as steroids or cyclophospha-
mides, both of which frequently aggravate underlying
infections and heightens the chances of opportunistic
infections. Chronic hepatitis B surface antigen
(HBsAg) carriers are known to have a higher risk of
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hepatitis-related mortality and morbidity when under-
going immunosuppressive therapy. We report a case
of RPGN in a hepatitis B virus (HBV) carrier that was
treated successfully by plasmapheresis, immunosuppres-
sive agents, and prophylactic lamivudine without aggra-
vation of HBV hepatitis.
CASE REPORT
A 35-year-old man who was a HBsAg carrier from
adolescence was admitted with a 1-month history of
recurrent gross hematuria. On admission, he looked ill
and his blood pressure was 130/80 mmHg. Physical
examinations were otherwise unremarkable. Laboratory
tests showed a high blood urea nitrogen level of 52.2
mg/dL, and a serum creatinine level of 4.4 mg/dL.
The levels of aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) were normal. C3 and
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A 35-year-old man, previously hepatitis B surface antigen (HBsAg) carrier, presented with gross
hematuria and heavy proteinuria that he had been suffering from for 1 month. Serum creatinine was
4.4 mg/dL. Renal biopsy showed pauci-immune crescentic glomerulonephritis. He received plasma-
pheresis and was treated with high-dose steroids and cyclophosphamide. Lamivudine was started for
the prevention of hepatitis B virus (HBV) activation. Serum creatinine and proteinuria were ameliorated
one week after the treatment. There was no sign of HBV activation after six months of treatment. We
report a case of rapidly progressive glomerulonephritis in a HBV carrier successfully treated with high
dose immunosuppressive therapy and prophylactic lamivudine.
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C4 levels remained within the normal range. Cytoplas-
mic antineutrophil cytoplasmic antibody (cANCA) or
perinuclear antineutrophil cytoplasmic antibody
(pANCA) was not detected. HBsAg was positive,
while hepatitis B e antigen (HBeAg) and anti-HBe
antibodies were negative. HBV-DNA quantitation was
negative. Urinalysis revealed heavy proteinuria (4.5
g/day) and hematuria. Creatinine clearance was 21.8
mL/min/1.73m2. Ultrasonograpahic findings showed in-
creased size and enhanced echogenecity with papillary
swelling in both kidneys, without evidence of hydro-
nephrosis. On the third day of admission, plasmaphe-
resis was performed using albumin solution for six
sessions. Renal biopsy was performed on the fifth day
of admission. Fibrocellular crescents were present in
three glomeruli of total ten glomeruli. The glomerular
basement membrane was not thickened. The tubules
showed focal degeneration, necrosis, and mild atrophy.
The interstitium was widened by moderate fibrosis
and mild mononuclear infiltrate. Immunofluorescence
microscopy showed minimal granular deposits of
fibrinogen in the mesangium (Fig. 1). Microscopic
examination showed linear IgG (+) and fibrinogen (+)
staining along the peripheral capillary wall. Granular
deposits of IgA (specks), C3 (specks), and fibrinogen
(+) were present in the mesangium. Electron micros-
copy showed a relatively even glomerular basement
membrane without electron densities. The mesangium
was expanded with increased mesangial cells and con-
tained some electron densities in mesangial matrix. In
light of these findings, the patient was diagnosed with
pauci-immune focal proliferative crescentic glomerulo-
nephritis.
Steroid pulse therapy was started on the 14th day
of admission with concomitant oral steroid therapy
(methylprednisolone 1 g/day intravenously for 3 days,
then prednisone 1 mg/kg/day), and pulse cyclopho-
sphamide treatment (1 g intravenously for 1 day).
Lamivudine (50 mg/day) was given prophylactically
in order to suppress the activation of HBV infection.
The serum creatinine level dropped to 1.3 mg/dL, and
proteinuria decreased to 1.55 g/day by the 21st day.
The patient was discharged with oral steroids and la-
mivudine. After discharge, the patient underwent five
more consecutive cyclophosphamide pulse treatments,
and his renal function steadily improved (Fig. 2). The
patient is currently well without any evidence of
activation of chronic hepatitis B.
DISCUSSION
The course of RPGN is often life threatening and
requires high dose corticosteroids and cyclophospha-
mide as a first-line treatment. However, infections
caused by immunosuppression, not vasculitis itself, is
the most common cause of death in RPGN patients,
Fig. 1. (A) A glomerulus shows mild endocapillary proliferation and a fibrocellular
crescent obstructiong the tubular pole (H&E, ×400). (B) Immunofluorescence
microscopy showed minimal nonspecific granular deposits of fibrinogen in the
mesangium.
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especially in chronic viral carrier patients. Reactivation
of HBV after cytotoxic or immunosuppressive therapy
in patients who are seropositive for HBsAg has been
well documented1-4). Additionally, HBV reactivation
can cause fatal fulminant hepatitis5, 6).
The mechanism of acute hepatic injury by HBV
reactivation after immunosuppressive treatment or che-
motherapy has not been fully elucidated. It has been
suggested that immunosuppression increases HBV
replication and ultimately results in viral infection of
hepatocytes. Withdrawal of immunosuppressive agents
results in the destruction of infected hepatocytes due
to immune function restoration. In cases of HBV reac-
tivation, immunosuppressive therapy is often delayed
or discontinued, leading to suboptimal treatment of
nephropathy.
Lamivudine is an oral synthetic nucleoside analog
that inhibits reverse transcription by causing chain
termination of nascent viral DNA in HBV infected cells.
Several studies have shown that prophylactic lamivu-
dine treatment prevents HBV replication in HBsAg-
positive patients with hematological malignancies or
solid tumors who have received cytotoxic chemothe-
rapy7, 8). Tang et al.9) reported that lamivudine im-
proves renal outcomes in patients with HBV infection
and membranous nephropathy. In the case reported by
Marco et al.10), renal and hepatic functions were im-
proved, and HBsAg was negatively conversed with
lamivudine and steroids in a patient with acute hepa-
titis B and RPGN. To our knowledge, our case is the
first to be reported with successful improvement of
renal function as a result of treatment with high dose
steroids, cyclophosphamide and prophylactic lamivudine
in a patient with RPGN and chronic hepatitis B infec-
tion. The optimum duration of lamivudine therapy is
not yet determined. Previous reports suggest that main-
tenance of lamivudine is recommended for at least
four to six months following chemotherapy7, 11, 12).
Others advocate that lamivudine should be maintained
for one to two years because HBV has been seen to
reactive even after 12 months following chemotherapy
13). In the present case, since the patient was taking
monthly cyclophsphamide treatments, lamivudine has
been continued for over six months. Although lamivu-
dine treatment in immunosuppressed patients is helpful,
there is still a limit due to the emergence of lamivu-
dine-resistant mutants. The cause of the resistance is
due to a point mutation in the tyrosine-methionine-
aspartate-aspartate (YMDD) motif of the virus' reverse
transcriptase, leading to the replacement of methionine
(M) by valine (V) or isolencine (I) (M204V/I) within
the polymerase domain. Previous studies reported that
Fig. 2. Clinical course of a patient. Abbreviations : HD, hospital day; PD, postdis-
charge.
- 624 -
Jung Eun Lee, et al. : A Case of RPGN in a HBV Carrier
20-40% of post-organ transplantation patients who
were HBV carriers developed YMDD mutants in the
first year of their transplantation14, 15). Chang et al.16)
also reported that YMDD mutation was present in
67% of patients with B viral hepatitis, following four
years of lamivudine therapy. The present case did not
show any signs of mutant formation up to the sixth
month of lamivudine treatment. A long-term follow-up
monitoring of mutant emergence may be necessary.
In conclusion, we report a case of RPGN with latent
HBV infection treated successfully with high-dose
steroids, cyclophosphamide, and prophylactic lamivu-
dine. Prophylactic lamivudine can be effective in pre-
venting the activation of HBV carrier with RPGN and
should be considered whenever treatment with high-
dose steroids or immunosuppressive therapy is initi-
ated.
REFERENCES
1) Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA,
Micetich KC, Young RC, Costa J: Reactivation of
chronic hepatitis B virus infection by cancer che-
motherapy. Ann Intern Med 96:447-449, 1982
2) Pariente EA, Goudeau A, Dubois F, Degott C, Gluck-
man E, Devergie A, Brechot C, Schenmetzler C, Ber-
nuau J: Fulminant hepatitis due to reactivation of
chronic hepatitis B virus infection after allogeneic
bone marrow transplantation. Dig Dis Sci 33:1185-
1191, 1988
3) Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G:
Prevalence of hepatitis B virus marker positivity and
evolution of hepatitis B virus profile, during che-
motherapy, in patients with solid tumours. Br J
Cancer 81:69-74, 1999
4) Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL,
Tam JS, Hui P, Leung NW, Zee B, Johnson PJ:.
Frequency of hepatitis B virus reactivation in cancer
patients undergoing cytotoxic chemotherapy: a pro-
spective study of 626 patients with identification of
risk factors. J Med Virol 62:299-307, 2000
5) Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK,
Todd D: Reactivation of hepatitis B virus replication
in patients receiving cytotoxic therapy. Report of a
prospective study. Gastroenterology 100:182-188, 1991
6) Nakamura Y, Motokura T, Fujita A, Yamashita T,
Ogata E: Severe hepatitis related to chemotherapy in
hepatitis B virus carriers with hematologic malignan-
cies. Survey in japan, 1987-1991. Cancer 78:2210-
2215, 1996
7) Idilman R: Lamivudine prophylaxis in HBV carriers
with haemato-oncological malignancies who receive
chemotherapy. J Antimicrob Chemother 55:828-831,
2005
8) Rossi G, Pelizzari A, Motta M, Puoti M: Primary
prophylaxis with lamivudine of hepatitis B virus
reactivation in chronic HBsAg carriers with lymphoid
malignancies treated with chemotherapy. Br J Hae-
matol 115:58-62, 2001
9) Tang S, Lai FM, Lui YH, Tang CS, Kung NN, Ho
YW, Chan KW, Leung JC, Lai KN: Lamivudine in
hepatitis B-associated membranous nephropathy.
Kidney Int 68:1750-1758, 2005
10) Di Marco V, De Lisi S, Li Vecchi M, Maringhini S,
Barbaria F: Therapy with lamivudine and steroids in
a patient with acute hepatitis B and rapidly progres-
sive glomerulonephritis. Kidney Int 70:1187-1188, 2006
11) Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai
LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R:
Early is superior to deferred preemptive lamivudine
therapy for hepatitis B patients undergoing che-
motherapy. Gastroenterology 125:1742-1749, 2003
12) Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D,
Safadi R: Lamivudine therapy for prevention of im-
munosuppressive-induced hepatitis B virus reactiva-
tion in hepatitis B surface antigen carriers. Blood
100:391-396, 2002
13) Idilman R: Duration of lamivudine prophylaxis in inac-
tive hepatitis B virus carriers with haemato/oncologi-
cal malignancies who receive chemotherapy. Gut 55:
1208-1209, 2006
14) Kletzmayr J, Watschinger B, Muller C, Demetriou D,
Puchhammer-Stöckl E, Ferenci P, Kovarik J: Twelve
months of lamivudine treatment for chronic hepatitis
B virus infection in renal transplant recipients. Trans-
plantation 70:1404-1407, 2000
15) Fontaine H, Thiers V, Chrétien Y, Zylberberg H, Pou-
pon RE, Bréchot C, Legendre C, Kreis H, Pol S: HBV
genotypic resistance to lamivudine in kidney recipients
and hemodialyzed patients. Transplantation 69:2090-
2094, 2000
16) Chang TT, Lai CL, Liaw YF: Incremental increases
in HBeAg seroconversion and continued ALT norma-
lization in Asian chronic HBV patients treated with
lamivudine for four years [Abstract]. Antiviral
Therapy 5(supplI):44, 2000
- 625 -
